Opdivo cabiralizumab combo falls flat in advanced pancreatic cancer

Opdivo + cabiralizumab combo falls flat in advanced pancreatic cancer

Five Prime Therapeutics and Bristol-Myers Squibb have confirmed that their randomised Phase 2 trial investigating the efficacy of the former’s cabiralizumab combined with the latter’s blockbuster immunotherapy Opdivo (nivolumab) in the treatment of advanced pancreatic cancer failed to meet its primary endpoint.

The combo fell short both with and without chemotherapy in a study of around 160 enrolled participants with locally advanced or metastatic or locally advanced or metastatic pancreatic cancer that had progressed despite having received one line of chemotherapy.  

read more

Original Article: Opdivo + cabiralizumab combo falls flat in advanced pancreatic cancer

More From BioPortfolio on "Opdivo + cabiralizumab combo falls flat in advanced pancreatic cancer"